Day Two At ODAC: Reviewing Drugs To Treat T-Cell Lymphoma In A Difficult Class

FDA appears to have more concerns with Gloucester's HDAC inhibitor Istodax (romidepsin) than with Allos' Folotyn (pralatrexate).